Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment
2010; Elsevier BV; Volume: 116; Issue: 21 Linguagem: Inglês
10.1182/blood.v116.21.1935.1935
ISSN1528-0020
AutoresMaría‐Victoria Mateos, Lucía López‐Corral, Miguel‐Teodoro Hernández, Pilar Giraldo, Javier de la Rubia, Felipe de Arriba, Laura Rosiñol, Juan José Lahuerta, Luis Palomera, Joan Bargay, Albert Oriol, Felipe Prósper, José García‐Laraña, Eduardo Olavarría, M.L. Martino, Ana-Isabel Teruel, José‐Ángel Hernández‐Rivas, Graça Esteves, José Mariz, Fernando Leal-da-Costa, Adrián Alegre, Jose-Luis Guzman, Ana López de la Guía, Nuria Quintana, José Luis Baquero, Jose Luis Monteserin Garcia, Jesús F. San Miguel,
Tópico(s)Cancer Treatment and Pharmacology
Referência(s)